AmerisourceBergen Corporation (NYSE:ABC) ended its day at $75.40 with the rising stream of 0.53% and its total traded volume was 2.89 million shares more than the average volume. The consensus mean EPS for the current quarter is at $-0.04 derived from a total of 3 estimates from the analysts who have weighed in on projected earnings. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.06) by $0.04.
Recent insider trends for Geron Corporation (NASDAQ:GERN) have caught the attention of investors.
In the most updated research from a number of analysts on Wall Street, the company gets 1 Buys and 0 Sell among 4 analysts. Stifel Nicolaus now has a $2.50 price objective on the biopharmaceutical company's stock.
Geron Corporation (GERN) has risen 4.28% since then. Finally, Zacks Investment Research raised shares of Geron Corp. from a "hold" rating to a "strong-buy" rating and set a $3.00 price target on the stock in a research note on Friday, August 5th.
Taking a broader look at the analyst consensus, according to 2 analysts Geron Corporation (NASDAQ:GERN)'s price will reach at $3.75 during 52 weeks. This works out to a net increase in ownership of 2.06 million shares, and suggests that institutions are feeling bullish about the stock. For the full year, analysts expect earnings to decline -10.53% yoy to -$0.17. Analyzing the last five market sessions, the stock was able to report -5.34% losses, thus going down by -17.79%, compared with its 200-day moving average of $2.44. BTIG Research reaffirmed a "neutral" rating on shares of Geron Corp.in a research note on Tuesday, September 20th. Needham & Company LLC restated a "hold" rating on shares of Geron Corporation in a research report on Friday, November 3rd. Revenue during the quarter was $507.84 million, representing -4% growth from $529.5 million in year-ago quarter. If you are reading this article on another publication, it was illegally copied and reposted in violation of global copyright and trademark legislation.
COPYRIGHT VIOLATION NOTICE: "Favorable Media Coverage Somewhat Unlikely to Affect Geron Corporation (GERN) Stock Price" was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2017/11/13/geron-corporations-gern-hold-rating-reaffirmed-at-stifel-nicolaus.html. Russell Investments Group Ltd. bought a new position in shares of Geron Corporation in the second quarter worth about $114,000. Tudor Investment Corp ET AL boosted its holdings in shares of Geron Corporation by 12.1% in the 1st quarter. IHT Wealth Management LLC bought a new position in shares of Geron Corporation in the second quarter worth about $122,000. Vanguard Group Inc. now owns 6,296,230 shares of the biopharmaceutical company's stock valued at $16,874,000 after buying an additional 465,626 shares in the last quarter. Parametric Portfolio Associates LLC raised its stake in shares of Geron Corporation by 59.4% in the second quarter. Tudor Investment Corp ET AL now owns 52,369 shares of the biopharmaceutical company's stock worth $119,000 after acquiring an additional 5,669 shares in the last quarter.
Currently Geron Corporation (NASDAQ:GERN)'s shares owned by insiders are 0.1%, whereas shares owned by institutional owners are 39.2%. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.